1984/01/01 by A. James Giannini, Catherine Nageotte, Robert H. Loiselle +2 · 37 citations
Biochemistry, Genetics and Molecular Biology · Medicine · Psychology · #Anesthesia #Antagonist #Chlorpromazine #Clozapine #Dopamine #Dopamine antagonist #Haloperidol #Internal medicine #Medicine #NMDA receptor #Pharmacological Receptor Mechanisms and Effects #Pharmacology #Phencyclidine #Pimozide #Psychiatry #Psychology #Psychosis #Receptor #Receptor Mechanisms and Signaling #Schizophrenia (object-oriented programming) #Schizophrenia research and treatment
paper · doi:10.3109/15563658408992586
published in Journal of Toxicology Clinical Toxicology 22(6), 573-579 (Marcel Dekker)
openalex publication_date 1984/01/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/06/26
Three neuroleptics were used to treat phencyclidine (PCP) psychosis. These included chlorpromazine, a DA-1 and DA-2 dopamine antagonist with noradrenergic effects; haloperidol, a predominantly DA-2 antagonist with noradrenergic effects; and pimozide a predominantly DA-2 antagonist with no noradrenergic activity. Three cohorts of randomly selected young white adult males were studied. Responses to haloperidol and pimozide were statistically equivalent and both were significantly superior to chlorpromazine. These results further support the role of the DA-2 receptor in PCP psychosis and tend to rule out a noradrenergic role. The authors therefore suggest that DA-2 blockers, such as haloperidol or pimozide be employed as treatment of choice in PCP psychosis.